Roche is in the early stages of evaluating a disposal of Esbriet, a lung disease drug that’s seen sales plummet amid competition from cheaper generics, after receiving inbound interest from potential suitors, people with knowledge of the matter told Bloomberg’s Dinesh Nair and Naomi Kresge.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RHHBY:
- New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
- Roche price target lowered to CHF 210 from CHF 230 at JPMorgan
- Roche price target lowered to CHF 265 from CHF 290 at Berenberg
- Roche price target lowered to CHF 250 from CHF 260 at Morgan Stanley
- FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
